Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Critically ill children are susceptible to nosocomial infections, which contribute to adverse outcomes. Deficiencies in the innate immunity lectin pathway of complement activation are implicated in a ...

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial In this single ...

The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...

SEATTLE, July 31, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it believes it has identified the proteins that activate the alternative pathway of the complement system, ...

Omeros ( ($OMER) ) has issued an update. On October 10, 2025, Omeros Corporation entered into an Asset Purchase and License Agreement with Novo ...

Shares of Omeros Corp. (NASDAQ:OMER) jumped 50.9% to $21.32 on Aug. 10 after it reported that six critically ill COVID-19 patients treated with its investigational lectin-pathway inhibitor, ...

"Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn" was originally created and published by Pharmaceutical ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at ...

Researchers have now discovered an important mechanism behind one of our most fundamental lines of immune function. Researchers from Aarhus University, Denmark, have now discovered an important ...